A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)

被引：0
|
作者：
Angevin, E.
Gruenwald, V.
Ravaud, A.
Castellano, D. E.
Lin, C. C.
Gschwend, J. E.
Harzstark, A. L.
Chang, J.
Wang, Y.
Shi, M. M.
Escudier, B. J.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hannover Med Sch, D-30623 Hannover, Germany
[3] Hop St Andre CHU, Bordeaux, France
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Tech Univ Munich, D-80290 Munich, Germany
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE I/II STUDY OF TKI258 (DOVITINIB), A FGFR AND VEGFR INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CANCER (MRCC): PRELIMINARY PHASE II RESULTS
    Angevin, E.
    Gruenwald, V.
    Lin, C.
    Ravaud, A.
    Lopez, J. A.
    Kruit, W.
    Tykodi, S.
    Gschwend, J.
    Harzstark, A.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 166 - 166
  • [2] Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
    Angevin, Eric
    Lopez-Martin, Jose A.
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Castellano, Daniel
    Soria, Jean-Charles
    Sen, Paramita
    Chang, Julie
    Shi, Michael
    Kay, Andrea
    Escudier, Bernard
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1257 - 1268
  • [3] A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic rental cell cancer: Phase I results.
    Angevin, E.
    Lin, C.
    Pande, A. U.
    Lopez, J. A.
    Gschwend, J.
    Harzstark, A. L.
    Shi, M.
    Anak, O.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
    Escudier, Bernard
    Gruenwald, Viktor
    Ravaud, Alain
    Ou, Yen-Chuan
    Castellano, Daniel
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Beall, Sarah
    Pirotta, Nicoletta
    Squires, Matthew
    Shi, Michael
    Angevin, Eric
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 3012 - 3022
  • [5] A phase II study of the VEGFR- and FGFR-inhibitior Dovitinib (TKI258) in patients with refractory advanced or metastatic renal cell cancer previously treated with VEGFR- or mTOR-targeted therapy
    Gruenwald, V
    Retz, M.
    Fenner, M.
    Wang, Y.
    Chang, J.
    Kay, A.
    Zuern, C.
    Gschwend, J.
    ONKOLOGIE, 2011, 34 : 11 - 11
  • [6] GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy
    Gruenwald, V
    Kube, U.
    Eichelberg, C.
    Zuern, C.
    Gschwend, J.
    ONKOLOGIE, 2012, 35 : 202 - 203
  • [7] Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma
    Dillon, Patrick Michael
    Moskaluk, Chris
    Fracasso, Paula M.
    Petroni, Gina R.
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Pharmacokinetic analysis of Asian patients in a phase 2 study of dovitinib (TKI258) in metastatic renal cell carcinoma
    Lin, C. C.
    Ou, Y. C.
    Chang, Y. H.
    Angevin, E.
    Gruenwald, V.
    Chang, J.
    Tan, E.
    Pirotta, N.
    Shi, M.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S191 - S191
  • [9] TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study
    Angevin, E.
    Lopez, J. A.
    Pande, A.
    Moldovan, C.
    Shi, M.
    Soria, J. C.
    Wang, X.
    Harzstark, A.
    Saro, J.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors
    Anne-Charlotte Dubbelman
    Alana Upthagrove
    Jos H. Beijnen
    Serena Marchetti
    Eugene Tan
    Kimberly Krone
    Suraj Anand
    Jan H. M. Schellens
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 653 - 663
12345